問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chang Gung Medical Foundation Chang Gung Memorial Hospital, Keelung (在職)

Division of Psychiatry

更新時間：2023-09-19

呂少鈞
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

6Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

呂少鈞

List

10Cases

2012-01-01 - 2014-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2020-08-16 - 2024-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting5Sites

Terminated2Sites

2025-11-01 - 2028-07-31

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2025-07-01 - 2030-05-31

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-12-01 - 2028-11-28

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2026-01-05 - 2028-09-13

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2021-05-31 - 2027-12-31

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

2013-04-30 - 2017-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2021-05-31 - 2027-12-31

Phase II/III

AN ADAPTIVE PHASE II/III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, TWO-PART, DOSE-FINDING, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF NABEN® (SODIUM BENZOATE), A D-AMINO ACID OXIDASE INHIBITOR, AS AN ADD-ON THERAPY WITH CLOZAPINE, FOR RESIDUAL SYMPTOMS OF REFRACTORY SCHIZOPHRENIA IN ADULTS

  • Condition/Disease

    Residual Symptoms of Refractory Schizophrenia in Adults

  • Test Drug

    NaBenR

Participate Sites
5Sites

Recruiting5Sites

2021-05-31 - 2023-11-29

Phase II/III

AN ADAPTIVE PHASE II/III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, TWO-PART, DOSE-FINDING, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF NABEN® (SODIUM BENZOATE), A D-AMINO ACID OXIDASE INHIBITOR, AS AN ADD-ON THERAPY WITH CLOZAPINE, FOR RESIDUAL SYMPTOMS OF REFRACTORY SCHIZOPHRENIA IN ADULTS

  • Condition/Disease

    Residual Symptoms of Refractory Schizophrenia in Adults

  • Test Drug

    NaBenR

Participate Sites
6Sites

Recruiting6Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB